Opus Genetics (NASDAQ:IRD) Releases Quarterly Earnings Results, Misses Estimates By $0.31 EPS

Opus Genetics (NASDAQ:IRD) announced its quarterly earnings results on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.31), FiscalAI reports. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.55 million.

Here are the key takeaways from Opus Genetics’ conference call:

• BEST1 showed encouraging early functional results: the company reported clearance of vitelliform material and improved retinal sensitivity in two low-dose cohort patients, and said its pivotal-trial endpoint is aligned with the FDA. The next, higher-dose cohort will include earlier-stage patients; management said consistent results there would help de-risk a phase III study.
• LCA5 is in a pivotal trial with results expected next year and a potential BLA filing in 2027 if the data hold, according to management.
• The company expects to begin dosing patients in its RDH12 and MERTK programs imminently, with data potentially arriving next year or in early 2028. Management also outlined possible readouts next year across these programs and BEST1 and LCA5.
• Management estimated the U.S. Best disease population at about 23,600, up from its prior estimate of 8,400, based on a company-commissioned survey of eye specialists. It described a targeted commercial launch approach, though the revised estimate has not yet been validated through actual launch experience.
• The company reported about $100 million in pro forma cash, including warrant exercises and an expected milestone, plus $70 million of available credit capacity; it said this supports a runway into 2029. Management views a potential 2028 priority review voucher sale as a possible next financing source.

Opus Genetics Stock Performance

Shares of IRD stock traded up $0.04 during mid-day trading on Wednesday, hitting $4.28. The company’s stock had a trading volume of 390,919 shares, compared to its average volume of 1,407,533. The stock has a market cap of $353.32 million, a price-to-earnings ratio of -3.17 and a beta of 0.81. Opus Genetics has a 52-week low of $1.70 and a 52-week high of $7.07. The business has a 50-day moving average price of $4.50 and a 200 day moving average price of $4.22.

More Opus Genetics News

These are some of the IRD news items that stood out recently:

• Positive Sentiment: Clinical and funding updates offered longer-term catalysts. Opus said its OPGx-BEST1 Cohort 2 dosing is complete, with data expected in Q1 2027; its OPGx-LCA5 Phase 3 trial is fully enrolled, and it plans to begin dosing in Q4 2026. The FDA also cleared its OPGx-RDH12 investigational application. The company expects cash to last into 2029, supporting upcoming development milestones. Q3 results and corporate update
• Neutral Sentiment: Reported short interest was zero. The November 10 update listed no shares sold short and a 0.0-day days-to-cover ratio, so it does not indicate notable short-covering pressure. Short interest report
• Negative Sentiment: Third-quarter results missed estimates. Coverage reported a per-share loss above consensus, and revenue was $1.14 million versus an estimate of $1.55 million. The earnings miss highlights continued operating losses and could weigh on sentiment despite the clinical progress. Q3 earnings coverage

Analyst Upgrades and Downgrades

IRD has been the subject of a number of analyst reports. Oppenheimer raised their price objective on shares of Opus Genetics from $10.00 to $20.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Chardan Capital reiterated a “buy” rating and issued a $16.00 target price on shares of Opus Genetics in a research note on Thursday, October 22nd. TD Cowen assumed coverage on shares of Opus Genetics in a report on Wednesday, July 29th. They set a “buy” rating on the stock. Wall Street Zen cut shares of Opus Genetics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Royal Bank Of Canada raised their price target on shares of Opus Genetics from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $13.29.

Insiders Place Their Bets

In related news, Director Fighting Blindness Foundation sold 556,000 shares of Opus Genetics stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total value of $2,757,760.00. Following the completion of the sale, the director directly owned 3,236,171 shares in the company, valued at approximately $16,051,408.16. This trade represents a 14.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Robert E. Gagnon sold 14,000 shares of the business’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $3.55, for a total value of $49,700.00. Following the completion of the transaction, the chief financial officer directly owned 542,375 shares of the company’s stock, valued at approximately $1,925,431.25. This trade represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 673,805 shares of company stock valued at $3,213,582. 11.70% of the stock is currently owned by corporate insiders.

Opus Genetics Company Profile

Opus Genetics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, rare conditions that can cause progressive vision loss. Its programs target specific genetic causes of these disorders, including mutations associated with Leber congenital amaurosis and retinitis pigmentosa. The company’s therapies are investigational and are designed to address the underlying genetic defects rather than only manage symptoms. Opus Genetics was formed through the combination of Opus Genetics and Ocuphire Pharma; the combined company took the Opus Genetics name and began trading on Nasdaq under the symbol IRD in 2024.